Seride Therapeutics Inc., a developer of new cell therapy, has completed 500 million yen in series A funding.

Seride Therapeutics Co., Ltd.
Seride Therapeutics Inc., a developer of new cell therapy, has completed 500 million yen in series A funding.
Accelerating the development of cell therapy products for the complete cure of leukemia, etc.

Seride Therapeutics Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo; President: Nobuyuki Arakawa) has established the “UTEC No. 5 Investment Business Limited Liability Partnership” with The University of Tokyo Edge Capital Partners Co., Ltd. as a general partner, Tsukuba Research Institute Implemented a third-party allotment capital increase underwritten by “Tsukuba SBI Regional Revitalization Fund Investment Business Limited Liability Partnership”, which has unlimited liability partners of Co., Ltd. and SBI Regional
Revitalization Support Co., Ltd., and “Techno Science Co., Ltd.” As a result, we have completed Series A financing totaling approximately 500 million yen.
With this funding, we will further accelerate the development of cell therapy products for blood cancers such as acute leukemia.

[Image 1

-Summary of Series A funding-
[Procurement amount] About 500 million yen
[Procurement method] Third-party allotment of new shares
[Underwriter] · UTEC No. 5 Investment Business Limited Liability Union        ・Tsukuba SBI Regional Revitalization Fund Investment Business Limited Liability Partnership
       ・Techno Science Co., Ltd.
Business of Seride Therapeutics
Hematological cancers such as leukemia are a field in which it has been pointed out that the incidence rate is increasing due to the aging population, and many countries around the world, not only in Japan, are eagerly awaiting the further development of curative treatment methods. is included. The regenerative medicine products that Seride Therapeutics is researching and developing will expand the possibilities of transplantation as a radical treatment for various hematological cancers. Hope it helps.
[Image 2d100408-4-499139371c5675a3773a-1.png&s3=100408-4-b7183fe94b910d2c5799d0b07b5f9d0c-3583x2019.png
-Purpose of fundraising-
Using the funds procured this time, we will conduct large-scale experiments using immunodeficient mice in Japan and promote activities to acquire non-clinical POC. After obtaining POC, we plan to launch our first cell therapy product from the US market after non-clinical safety tests and clinical trials in the US, and have already established a supply chain including manufacturing in the US. We are proceeding with specific negotiations with various companies with the aim of
[Image 3d100408-4-2a14e5fc285008f0b4f5-2.jpg&s3=100408-4-ba2a29cee6e949953db04c314af43947-1060x599.jpg

Comments from investors
-Atsushi Usami, Director and Partner, The University of Tokyo Edge Capital Partners Co., Ltd.-
My first encounter with Seride Therapeutics was a year and a half ago. President Arakawa and his team discussed how to proceed with development in order to deliver groundbreaking technologies from Japan to clinical sites around the world and to people with diseases in an appropriate and prompt manner. I have a very fond memory of the days when we thought through our business plans while exchanging wisdom with everyone. From basic research to product development, from development in Japan to development in the United States, we were able to welcome this day of fundraising with people who have gathered together with their thoughts as we move forward with our business. I am very happy. I am very much looking forward to continuing to work closely with all of you as we move forward.
-Mr. Kazunori Takahashi, Chief Researcher, Consulting Department, Tsukuba Research Institute-
The origin of Cereide Therapeutics’ technology lies in the creativity and enthusiasm that led to the success of culturing human
hematopoietic stem cells, which was said to be difficult, using polyvinyl alcohol, a common ingredient that is also found in commercially available liquid glue. I understand. After that, it was sublimated into human hematopoietic stem cell amplification technology by improving the technology using new chemically synthesized compounds.
We strongly agree with the vision of applying this technology to deliver cell therapy products to patients suffering from blood cancer, and we have decided to make this investment because we want to realize that world together. We hope that Cereide Therapeutics’ innovative cell therapy products will contribute to improving the quality of life of blood cancer patients around the world.
– Mr. Shoichi Kobayashi, Representative Director, Techno Science Co., Ltd. – We are delighted to be able to participate in the wonderful
initiatives that Cereido Therapeutics is aiming for through this investment. We would like to support the growth of Cereide
Therapeutics, Inc. to solve the problems of treating intractable blood and immune diseases with the world’s most advanced “extracorporeal expansion technology of hematopoietic stem cells”. .
Comment from Nobuyuki Arakawa, CEO of Seride Therapeutics Co., Ltd. [Image 4d100408-4-5309c48ee823bb68d509-3.jpg&s3=100408-4-0ea74bcafde88e7b47ec5dc5cf80eaa2-1254x1067.jpg
In Series A, the company’s first full-scale funding round, we met with investors who recognized the potential of our technology and the significance of contributing to society, and secured the necessary funds for future product development. I am very happy that I was able to do it. With the expectations of each investor in mind, we will further promote our product development activities.

-About Seride Therapeutics Co., Ltd.-
Cerite Therapeutics Inc. is a bio-venture company established in 2020. It uses hematopoietic stem cells, which are the source of human blood, to treat intractable blood diseases including blood cancers such as leukemia. A company that conducts research and development of useful regenerative medicine products. In the field of hematologic cancer treatment, a certain amount of hematopoietic stem cells must be transplanted for a complete cure. Our business aims to safely and efficiently increase these hematopoietic stem cells and provide them to society as new regenerative medicine products.
【About us】
Representative: Nobuyuki Arakawa, President and CEO
Head office location: 7-3-1 Hongo, Bunkyo-ku, Tokyo University of Tokyo South Research Building Entrepreneur Lab
Year of establishment: October 2020
Capital: 560 million yen (including capital reserve)
Business description: Research and development of regenerative medicine products using human hematopoietic stem cells

Details about this release:


Leave a Reply

Your email address will not be published.

%d bloggers like this: